Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT

Solid Biosciences Inc. (NASDAQ:SLDB) is one of the best stocks to invest in for a quick return.

Solid Biosciences Inc. (NASDAQ:SLDB)

Robotic arms performing diagnostic tests in a healthcare technology lab.

Citi initiated coverage on Solid Biosciences Inc. (NASDAQ:SLDB) with a ‘Buy’ rating, setting its price target at $14 on June 26, 2025. Citing strong potential in the Duchenne Muscular Dystrophy (DMD) market, the analyst discussed a compelling valuation gap, with the company’s current $100 million total firm value sitting well below its projected peak U.S. sales potential of around $3 billion.

Furthermore, safety concerns recently erupted surrounding a competitor’s DMD therapy, which has resulted in increased attention toward Solid Biosciences Inc.’s (NASDAQ:SLDB) SGT-003 because of no signs of liver toxicity caused by it. Thus, several analysts maintain ‘Buy’ or ‘Overweight’ ratings, with price targets ranging from $14 to $20.

The company is focused on developing gene therapies for neuromuscular and cardiac conditions, with a pipeline led by SGT-003 for DMD. Moreover, its strong cash position backs Solid Biosciences Inc.’s (NASDAQ:SLDB) next phase of development. It is one of the best stocks.

While we acknowledge the potential of SLDB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLDB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 7 Best Fertilizer Stocks to Buy According to Hedge Funds and Growth Stock Portfolio: 12 Companies with At Least 30% Annual Growth Rates.

Disclosure: None.